Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4512688 | 0.85 | KMT2A (0.65) | P2RX7MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL4511636 | 0.81 | KDM4E (0.66) | P2RX7MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL4515572 | 0.79 | MAPT (0.67) | P2RX7MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL4523295 | 0.78 | CYP1A2 (0.64) | P2RX7MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL8393737 | 0.77 | RAB9A (0.64) | MEN1KMT2ARAB9ANPC1DRD2 | |
| SCHEMBL4519320 | 0.77 | KMT2A (0.55) | P2RX7MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL7363572 | 0.75 | CYP1A2 (0.48) | — | |
| SCHEMBL3722958 | 0.75 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL4511608 | 0.75 | KMT2A (0.52) | P2RX7MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL4515148 | 0.75 | CLPP (0.57) | P2RX7MEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | P2RX7 3946/4885MEN1 1254/4885KMT2A 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.